BACPHAR
Bacil Pharma financials
- Market cap
- ₹82 Cr
Quarterly results
Q1 FY27: net profit down 103.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -0 | -0 | -0 +57% | -0 +67% | -0 +0% | -0 +82% |
| Net profit | 0 | -0 | 0 | 1 | 0 −98% | 0 +167% | 1 +3000% | -0 −103% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −46.9% 1Y
1Y: ₹35 on 8 Sept 2025 → ₹18.58. High ₹59.89 (10 Apr 2026), low ₹11.21 (25 Aug 2026).
Financials, as filed
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | ₹-0 Cr | ₹-0 Cr | ₹-0 Cr |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹-0 Cr | ₹0 Cr | ₹1 Cr |
| Cash from operations | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Free cash flow | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| ROCE | -13.1% | -1.0% | 3.9% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹14 Cr | ₹14 Cr |
| Reserves | ₹-5 Cr | ₹-5 Cr | ₹-5 Cr | ₹-5 Cr | ₹11 Cr | ₹11 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other liabilities | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr |
| Total liabilities | ₹4 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹26 Cr | ₹27 Cr |
| Fixed assets | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹21 Cr | ₹24 Cr |
| Other assets | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹3 Cr |
| Total assets | ₹4 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹26 Cr | ₹27 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −0.20 pp while the public added +0.20 pp. The shareholder count shrank 3% to 7,326.
- Public
- 100.0%
Since Jun 2025
- Promoters −0.20 pp
- Public +0.20 pp
How it drifted, 12 quarters
Over this window promoters fell from 42.7% to 0.0% — −42.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 42.7%, Public 57.3%.Dec '23: Promoters 42.7%, Public 57.3%.Mar '24: Promoters 42.7%, Public 57.3%.Jun '24: Promoters 42.7%, Public 57.3%.Sep '24: Promoters 20.7%, Public 79.3%.Dec '24: Promoters 10.6%, Public 89.4%.Mar '25: Promoters 0.2%, Public 99.8%.Jun '25: Promoters 0.2%, Public 99.8%.Sep '25: Promoters 0.1%, Public 99.9%.Dec '25: Promoters 0.1%, Public 99.9%.Mar '26: Public 100.0%.Jun '26: Public 100.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Niraj Rajnikant Shah newly disclosed 6.44% held
- Vishal Mahesh Waghela newly disclosed 2.09% held
- Dinesh Ishvarbhai Lalwani newly disclosed 1.05% held
- Chhaya Gaurang Shah +0.24 pp 6.66% held
The same filing shows 2 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Bacil Pharma Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Vicky Pratapbhai Shah | 16.59% | unchanged |
| Nikita Hiren Patel | 10.07% | −9.37 pp |
| Manubhai Amrutlal Shah | 9.86% | −8.48 pp |
| Chhaya Gaurang Shah | 6.66% | +0.24 pp |
| Niraj Rajnikant Shah | 6.44% | newly disclosed |
| Manmohan Jagdishprasad Ghuwalewala | 4.18% | unchanged |
| Navin Keshrimal Mehta | 2.17% | unchanged |
| Vishal Mahesh Waghela | 2.09% | newly disclosed |
| Deepa Navin Mehta | 1.74% | unchanged |
| Hemang Rajendra Doshi | 1.72% | unchanged |
| Saroj Kishor Mehta | 1.16% | unchanged |
| Dinesh Ishvarbhai Lalwani | 1.05% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Bacil Pharma Ltd.
Guides on how to read this kind of business and the numbers that matter.